Europe's Clinical Trial Registry Has a Transparency Problem Nobody's Fixing
A new analysis found that fewer than half of European clinical trials post results on time, with only 42% achieving complete disclosure. The EU has the laws and the fining authority to fix this; what it lacks is the will to enforce them.
Imagine running a restaurant where health inspectors never actually check if you're storing food safely. You've got rules on the books. Signs on the wall. But nobody's enforcing anything, and half the kitchen is a mess.
That's roughly the state of Europe's clinical trial registry right now.
Half the Results Are MIA
A new analysis, reported by STAT News, examined 234 clinical trials whose results were legally due on Europe's clinical trial registry. The findings are bleak: fewer than half posted results within the required timeframe. Only about 42% had fully complete result summaries.
Let that sink in. The European Union has rules that say sponsors must publish trial results within 12 months of a trial's end. For pediatric trials, that window shrinks to six months. And yet, more than half of the trials reviewed simply didn't comply.
The researchers behind the analysis didn't mince words, concluding that EU and national regulators "have so far not delivered the promised 'high levels of transparency never seen before for clinical trials.'"
Registration Is Fine. Disclosure Is Not.
Here's what makes this particularly frustrating: the registry data itself is actually pretty clean. Over 99% of expected registration data fields were filled in correctly across the 234 trials examined. Sponsors are dutifully signing up their trials. They're entering all the right details at the start.
But when it comes time to share what they actually found? Crickets.
It's like filling out a job application perfectly, acing the interview, and then just never showing up for work. The paperwork looks great. The follow-through is terrible.
A Problem That's Been Hiding in Plain Sight
This isn't exactly a surprise if you've been paying attention. Larger analyses of the EU Clinical Trials Register (EUCTR) have consistently found that roughly half of completed trials are missing results. One major study in the BMJ looked at over 7,000 trials and found only as required.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
49.5% had posted results
When researchers tried to include trials that were probably completed but had outdated status information on the registry, the picture got even worse: an estimated 64% may be missing results entirely.
The pattern is clear and stubbornly consistent. Year after year, about half the evidence from European clinical trials stays locked away.
Who's Actually Doing Their Homework?
Not all sponsors are equally guilty. Pharmaceutical companies report results at significantly higher rates than academic and university-run trials. Industry compliance has climbed to around 86%, according to EMA figures from 2022. Non-commercial sponsors (universities, hospitals, charities) sat at about 64%, which sounds decent until you look at how recently that number was abysmal.
Back in 2019, non-commercial sponsors had a compliance rate of just 24%. A focused review of 30 European universities found results missing for 83% of their trials. The academic world, which prides itself on scientific rigor, has been one of the worst offenders.
Industry isn't off the hook, though. An 86% compliance rate still means roughly one in seven pharma-sponsored trials isn't meeting the legal deadline. When you're talking about drugs that real patients are taking, that gap matters.
Why This Isn't Just a Bureaucratic Problem
Missing trial results aren't a filing error. They're a threat to how doctors make decisions.
Evidence-based medicine depends on seeing all the data, not just the results companies or researchers feel like sharing. When negative or inconclusive trials go unreported, systematic reviews and clinical guidelines get skewed. Doctors end up recommending treatments based on an incomplete picture. Patients can be harmed by drugs whose risks were quietly buried in an unpublished trial.
Meta-analytic evidence shows that industry-sponsored trials have 3.5 times greater odds of reporting pro-industry conclusions. Selective publication amplifies that bias. Every unreported trial is a missing puzzle piece that could change the whole picture.
Health Action International estimates that at least 5,488 trial results that national regulators are directly responsible for remain unpublished, with Italy, the Netherlands, Spain, and France among the biggest offenders.
The Rules Exist. The Teeth Don't.
The EU Clinical Trials Regulation gives national authorities the power to take action: corrective measures, trial suspension, even revocation of authorization. Seven major EU countries now have explicit authority to fine sponsors up to roughly €250,000 for non-reporting.
But here's the catch: almost nobody is actually pulling the trigger. Few examples of real penalties have been publicized. Advocates describe a "gap between regulatory powers on paper and their practical use." The enforcement toolbox is fully stocked; it's just gathering dust.
EMA has acknowledged the problem, committing to add compliance metrics to its quarterly reports and remind sponsors of their obligations through national contact points. Transparency advocates see this as a start, but hardly enough. IQWiG's Jürgen Windeler has argued that sanctions are "seemingly required" and proposed that funders refuse future grants to researchers who haven't reported results from past projects.
Can CTIS Actually Fix This?
Europe's new Clinical Trials Information System (CTIS) was supposed to be the answer. It replaced the older EudraCT system and, as of January 2025, all ongoing EU trials must run through it. The platform has processed around 13,000 applications and made over 11,000 trials publicly searchable.
Revised transparency rules, effective since June 2024, removed most options for sponsors to delay publication. Key documents now follow standardized publication timelines based on trial type and phase.
On paper, CTIS is a significant upgrade. But the June 2026 analysis suggests the real bottleneck was never the technology. It was the willingness to enforce the rules. A shiny new database doesn't matter much if sponsors still face zero consequences for ignoring deadlines.
How Europe Compares to the U.S.
The comparison with ClinicalTrials.gov isn't flattering for either side, though Europe has been catching up. U.S. compliance under the FDAAA has plateaued around 40% with no clear improvement since 2018. Europe's legacy EUCTR data showed rapid improvement from about 50% to 84% overall compliance by 2022.
But those numbers come with asterisks. About 16% of trials listed on both registries have mismatched status information, meaning some "ongoing" European trials may actually be completed and overdue. The real compliance rate could be lower than official figures suggest.
The Bottom Line
Clinical trial transparency isn't some abstract regulatory checkbox. It's the foundation that evidence-based medicine is built on. When half the results from European trials go unreported, every treatment guideline, every prescribing decision, every patient conversation happens with incomplete information.
The EU has the laws. It has the systems. It even has the fining authority. What it doesn't seem to have, at least not yet, is the political will to use them. Until that changes, Europe's promise of unprecedented clinical trial transparency remains exactly that: a promise.
5 min read
Adaptive Biotech Is Breaking Up With Itself
Adaptive Biotechnologies is splitting its profitable cancer diagnostics business from its early-stage drug discovery platform into two separate companies. The move follows a growing industry trend of corporate breakups designed to let fundamentally different businesses attract the right investors.
